メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

  • Michael Schiff
  • , Tsutomu Takeuchi
  • , Roy Fleischmann
  • , Carol L. Gaich
  • , Amy M. DeLozier
  • , Douglas Schlichting
  • , Wen Ling Kuo
  • , Ji Eon Won
  • , Tara Carmack
  • , Terence Rooney
  • , Patrick Durez
  • , Saeed Shaikh
  • , Rodolfo Pardo Hidalgo
  • , Ronald van Vollenhoven
  • , Cristiano A.F. Zerbini

研究成果: Article › 査読

59   !!Link opens in a new tab 被引用数 (Scopus)

抄録

Background: This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and naïve to biological DMARDs. Methods: Patients were randomized 4:3:4 to MTX administered once weekly (N = 210), baricitinib monotherapy (4 mg once daily (QD), N = 159), or combination of baricitinib (4 mg QD) and MTX (baricitinib + MTX, N = 215). PROs included the Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), duration of morning joint stiffness (MJS), worst joint pain, worst tiredness, Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA), Short Form 36 version 2, Acute (SF-36); and EuroQol 5-Dimensions (EQ-5D) Health State Profile. Comparisons were assessed with analysis of covariance (ANCOVA) and logistic regression models. Results: Compared to MTX, patients in both baricitinib groups reported greater improvement (p ≤ 0.01) in HAQ-DI, PtGA, pain, fatigue, worst join pain, SF-36 physical component score, and EQ-5D at weeks 24 and 52. For the SF-36 mental component score, patients in both baricitinib groups reported statistically significant improvements (p ≤ 0.01) at week 52 compared to MTX-treated patients. Statistically significant improvements (p ≤ 0.05) were observed with the WPAI-RA for the baricitinib groups vs. MTX at week 24 and for the WPAI-RA daily activity and work productivity measures for baricitinib + MTX at week 52. Conclusions: In this study, baricitinib alone or in combination with MTX, when used as initial therapy, resulted in significant improvement compared to MTX in the majority of the pre-specified PRO measures. Trial Registration: ClinicalTrials.gov, NCT01711359. Registered on 18 October 2012.

本文言語English
論文番号208
ジャーナルArthritis Research and Therapy
巻19
号1
DOI
出版ステータスPublished - 2017 9月 18

ASJC Scopus subject areas

  • 免疫アレルギー学
  • リウマチ学
  • 免疫学

フィンガープリント

「Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル